Insight Molecular Diagnostics Inc. Other Accounts Payable and Accrued Liabilities
Insight Molecular Diagnostics Inc. (IMDX) had Other Accounts Payable and Accrued Liabilities of $2.81 million as of 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Notes › Payables and Accruals
us-gaap:OtherAccountsPayableAndAccruedLiabilities · last filed 2021-05-17
- 2021-03-31: Other Accounts Payable and Accrued Liabilities $2.81M.
- 2020-12-31: Other Accounts Payable and Accrued Liabilities $1.60M.
- 2020-09-30: Other Accounts Payable and Accrued Liabilities $636.00K.
- 2020-06-30: Other Accounts Payable and Accrued Liabilities $743.00K.
| Period end | Other Accounts Payable and Accrued Liabilities |
|---|---|
| 2021-03-31 | $2.81M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $1.60M 10-Q · filed 2021-05-17 |
| 2020-09-30 | $636.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $743.00K 10-Q · filed 2020-07-29 |
| 2020-03-31 | $1.18M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $1.32M 10-K · filed 2021-03-19 |
| 2019-09-30 | $1.05M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.51M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $1.61M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $806.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $440.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $560.00K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $1.21M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $406.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |